ELI LILLY

ELI LILLY

approved_indications FDA Approved Biologics and Pending Applications


Basaglar®

insulin glargine
aBL 205692

Cyramza®

ramucirumab
BL 125477

Emgality®

galcanezumab-gnlm
BL 761063

Erbitux®

cetuximab
BL 125084

Forteo®

teriparatide
NDA 021318

Glucagon®

glucagon
BL 20928

Humalog®

insulin lispro recombinant
BL 020563

Humalog® Mix 50/50 / Humalog® Mix 50/50 KwikPen®

insulin lispro protamine recombinant; insulin lispro recombinant
BL 021018

Humalog® Mix 75/25 / Humalog® Mix 75/25 KwikPen®

insulin lispro protamine recombinant; insulin lispro recombinant
BL 021017

Humatrope®

somatropin
BL 019640

Humulin® R / Humulin® R KwikPen®

insulin human
BL 018780

Insulin Lispro (Authorized Generic)

insulin lispro recombinant
aBL 020563

Lartruvo®

olaratumab
BL 761038

Lyumjev®

insulin lispro-aabc
BL 761109

Omvoh

mirikizumab-mrkz
BL 761279

Portrazza®

necitumumab
BL 125547

Rezvoglar

insulin glargine-aglr
aBL 761215

Taltz®

ixekizumab
BL 125521

Trulicity®

dulaglutide
BL 125469

approved_indications Approved Foreign Follow-On Biologics / Biosimilars


Biosimilars Approved In Canada

Basaglar (insulin glargine recombinant) (Eli Lilly) (August-2015)

Biosimilars Approved In The E.U.

Abasaglar (insulin glargine recombinant) (Eli Lilly / Boehringer Ingelheim) (September-2014)

Biosimilars Approved In Australia

Basaglar (insulin glargine recombinant) (Eli Lilly Australia) (November-2014)

Biosimilars Approved In Japan

Insulin glargine BS (insulin glargine recombinant) (Eli Lilly / Boehringer Ingelheim) (December-2014)

approved_indications Inter Partes Review Proceedings


ERBITUXIPR2016-00458
TALTZPGR2019-00043
AJOVY / EMGALITYIPR2018-01422
IPR2018-01423
IPR2018-01424
IPR2018-01425
IPR2018-01426
IPR2018-01427
IPR2018-01710
IPR2018-01711
IPR2018-01712
IPR2022-00738
IPR2022-00739
IPR2022-00796

approved_indications U.S. Patent Litigations


ERBITUX2:13-cv-07248 (C.D. Cal.)
2:15-cv-06133 (E.D. Pa.)
4:13-cv-00919 (N.D. Cal.)
FORTEO1:16-cv-00596 (S.D. Ind.)
1:21-cv-01922 (S.D. Ind.)
1:22-cv-01354 (D. Del.)
TALTZ3:18-cv-01518 (S.D. Cal.)
AJOVY / EMGALITY1:17-cv-12087 (D. Mass.)
1:18-cv-10242 (D. Mass.)
1:18-cv-12029 (D. Mass.)
1:21-cv-10954 (D. Mass.)
ERBITUX / GENENTECH CABILLY2:13-cv-07248 (C.D. Cal.)
4:13-cv-00919 (N.D. Cal.)
LANTUS / LANTUS SOLOSTAR / BASAGLAR1:14-cv-00113 (D. Del.)
1:14-cv-00884 (D. Del.)

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha